Clinical Trials on Age-associated Muscle Loss in Germany

Total 12 results

University of Erlangen-Nürnberg Medical School

Unknown

Effects of WB-EMS and Specific Dietary Supplements on Cancer Patients

Cancer | Muscle Weakness | Weight Loss | Cancer Cachexia | Muscle Loss

Germany
University of Erlangen-Nürnberg Medical School

Completed

Effects of WB-EMS and Dietetic Treatment on Cancer Patients

Cancer | Muscle Weakness | Weight Loss | Cancer Cachexia | Muscle Loss

Germany
Charite University, Berlin, Germany
German Research Foundation

Completed

Effects of Negative Energy Balance on Muscle Mass Regulation

Obesity | Weight Loss | Insulin Sensitivity/Resistance | Skeletal Muscle

Germany
Charite University, Berlin, Germany
German Research Foundation

Completed

Hormonal Regulation of Body Weight Maintenance

Obesity | Insulin Resistance | Weight Loss | Weight Gain | Hormone Disturbance | Skeletal Muscle | Adipose Tissue

Germany
Novartis Pharmaceuticals

Completed

Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients (B-Confident)

Cryopyrin-associated Periodic Syndromes (CAPS) | Familial Cold Autoinflam Syn (FCAS) | Muckle-wells Syn (MWS) | Neonatal Onset Multisystem Inflam Disease (NOMID)

Switzerland, United States, Germany, Norway, Austria
GlaxoSmithKline
Parexel

Completed

Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)

Cachexia

Germany, United States, United Kingdom
Charite University, Berlin, Germany

Completed

Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS) (ACCILTRA1)

Schnitzler Syndrome | Muckle-Wells Syndrome

Germany
Novartis

Completed

Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Familial Cold Autoinflammatory Syndrome | Cryopyrin-Associated Periodic Syndromes | Neonatal Onset Multisystem Inflammatory Disease | Muckle Wells Syndrome

United States, Germany, Italy, Spain, United Kingdom, Turkey, France, Belgium, India
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Familial Cold Autoinflammatory Syndrome | Muckle-Wells Syndrome | Neonatal Onset Multisystem Inflammatory Disease | Cryopyrin-associated Periodic Syndromes

Germany, France, Belgium, Canada, Spain, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Familial Cold Autoinflammatory Syndrome | Muckle-Wells Syndrome | Neonatal Onset Multisystem Inflammatory Disease | Cryopyrin-associated Periodic Syndromes

Germany, France, Belgium, Canada, Spain, Switzerland, United Kingdom
Novartis

Completed

Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome (REMITTER)

Muckle Wells Syndrome

United States, Spain, United Kingdom, France, Germany, India
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery

Muscle Wasting (Atrophy) After Hip Fracture Surgery

Colombia, Belgium, Hungary, Taiwan, Spain, Czechia, United States, France, Germany, Turkey, Japan, Russian Federation, United Kingdom, Argentina, Australia, Mexico, Chile, Switzerland, Austria

Clinical Trials on Age-associated Muscle Loss in Germany

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations